Merck KGaA adds 350 workers at French site to build capacity for 'single-use' tech for Covid-19 vaccines, therapies

Kyle Blankenship

Germany’s Merck KGaA has seen a growth spurt in recent months driven by sky-high demand for Covid-19 drugs and vaccines. Now, the company is fleshing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck KGaA adds 350 workers at French site to build capacity for 'single-use' tech for Covid-19 vaccines, therapies

Kyle Blankenship

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Mer­ck KGaA adds 350 work­ers at French site to build ca­pac­i­ty for 's­in­gle-use' tech for Covid-19 vac­cines, ther­a­pies

Kyle Blankenship

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Merck KGaA adds 350 workers at French site to build capacity for 'single-use' tech for Covid-19 vaccines, therapies

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life